A Visionary Approach to Uveitis: Tarsier Pharma’s Disruptive Innovation

Click here to watch the video version of this podcast.

In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.

Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.

In this episode, you’ll learn:
🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.
🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.
🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.
🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.
🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.

🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!

Resources:
Dr. Robert Rothman: https://ois.net/robert-rothman-md/
Daphne Haim-Langford, PhD: https://il.linkedin.com/in/daphnehaimlangford
Ashley Kline: https://www.linkedin.com/in/ashleykline